Allergan Warning May Prompt Suits By AGs: Expert
“In recent warning-letter memory, I haven't seen one that's this harsh,” said Arnie Friede, principal with the firm of Arnold I. Friede & Associates. “Given the tone of the letter, it would not at all surprise me if the states picked up on this.”
Thomas Abrams, director of the FDA's Division of Drug Marketing, Advertising and Communications,...
To view the full article, register now.